Recent research showed that ZNF703 is amplified in approximately 15% of breast tumors [23, 25–27], which is only less than HER2 and cyclin D1 (CCND1) [26, 28, 29], especially in Luminal B molecular subtypes [9–11, 29]; thus, more attention has been focused on ZNF703. This evidence concerns the gene CCND1 and breast neoplasm.